MOTHER x Yogasleep Vue Baby Monitor New York Event
The early years of motherhood can be tough—which is why it brings us no greater joy than to create an event that pampers new and…
-
-
B.C. case shows how courts offer crucial oversight when lives are at stake
A British Columbia judge recently issued an interim injunction, blocking a B.C. physician from providing medically assisted death (MAiD) to a 53-year-old woman. Her MAiD…
-
New ear acupuncture may help reduce migraine pain
A new treatment has shown promise in reducing migraine pain with targeted ear acupuncture, opening the door to therapy that could be used as a…
-
The Critical Role of Human Oversight and Continuous Validation
Dr. Sheila Bond, Director of Clinical Content Strategy at Wolters Kluwer Health “Above all else, do no harm.” The Hippocratic Oath remains the ultimate guiding…
-
Editor’s Pick: Retrospective Cohort Study of Long-Term Outcomes Associated with Severe Hyponatraemia
Key Points 1. Severe hyponatraemia was associated with an 18-month mortality of 40.1%, rising to 50% among patients who failed to show any sodium increase…
-
Change Long Overdue in Black Maternal Health – Kelli Sheppard
The fourth annual Black Maternal Health Week wrapped up April 17th and I am still reeling from everything I absorbed during that phenomenal week. It…
-
Midwifery Today The Power of Cultural Conditioning The heart and science of birth
Photo by mauro mora There are countless ways to classify the 5000 or so species of mammals. Among them is the very special case of…
-
Honor 600 review: Saved by a swift price cut
To help us provide you with free impartial advice, we may earn a commission if you buy through links on our site. Learn more On this…
-
‘The next big thing’: Newfund raises €60m to back brain technologies
Paris-based early-stage VC Newfund has closed a €60m fund dedicated to brain technologies in a bid to tackle a small but fast-growing market. The firm…
-
Icotrokinra Psoriasis Trial Shows Durable Response
ADULTS with moderate-to-severe plaque psoriasis treated with the oral interleukin-23 (IL-23) receptor inhibitor icotrokinra maintained high rates of skin clearance and symptom improvement through 52…
